Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Launched by GLAXOSMITHKLINE · Apr 29, 2025

Keywords

ClinConnect Summary

The ENDURA-2 clinical trial is studying a new medication called depemokimab for adults aged 40 to 80 with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) that is linked to type 2 inflammation. This trial aims to see how well depemokimab works and how safe it is when added to the current standard treatments for COPD. To participate, individuals must have a history of COPD, have experienced frequent flare-ups in the past year, and be currently using specific inhaler therapies. Additionally, they need to have a higher than normal level of certain white blood cells called eosinophils.

Participants in this trial can expect to receive either the new treatment or a placebo (a non-active treatment) while continuing their regular COPD medications. It’s important to note that the trial is currently not recruiting participants, so no one can join just yet. This study is an essential step in finding better treatments for COPD, which can significantly impact people's daily lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the Informed consent
• • Elevated Blood Eosinophil Count (BEC)
• * Moderate to severe COPD with frequent exacerbations, defined as:
• • A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year
• • A post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ratio of \< 0.70 and a post-bronchodilator FEV1 \>30 percent (%) and \<= 80% predicted normal values
• • A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening
• • COPD assessment test (CAT) score \>=10 at Visit 1
• • Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years.
• • Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1
• • Body mass index (BMI) \>=16 kilogram per square meter (kg/m\^2)
• • Male and eligible female participants
• Exclusion Criteria:
• The following subjects are excluded:
• • Participants with a current or prior physician diagnosis of asthma
• • Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease
• • Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1
• • Lung resection: Participants with a history of or plan for lung volume reduction surgery / endobronchial valve procedure.
• • Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1
• • Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day
• • Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension
• • Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \[BiPAP\] or Continuous Positive Airway Pressure \[CPAP\])
• • Unstable cardiovascular disease or arrhythmia
• • Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)